NCT06692829

Brief Summary

Considering the paucity of studies on robotic hand therapy, larger-scale and long-term follow-up studies are needed. The aim in this study is to demonstrate the effectiveness of robot-assisted hand therapy in patients with chronic stroke and to compare this effectiveness in patients with different Brunnstrom stages.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable stroke

Timeline
Completed

Started Dec 2024

Shorter than P25 for not_applicable stroke

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 3, 2024

Completed
3 months until next milestone

First Posted

Study publicly available on registry

November 18, 2024

Completed
13 days until next milestone

Study Start

First participant enrolled

December 1, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

November 18, 2024

Status Verified

November 1, 2024

Enrollment Period

7 months

First QC Date

September 3, 2024

Last Update Submit

November 15, 2024

Conditions

Keywords

strokehemiplegiarobotic rehabilitationhand function

Outcome Measures

Primary Outcomes (4)

  • Brunnstrom Staging

    is a test that evaluates the motor development of hemiplegic patients. In this test, the neurophysiological recovery process of the hemiplegic patient is defined as 6 stages. According to this staging, the lowest stage is stage 1 (flaccid, no voluntary movement stage), and the highest stage is stage 6 (isolated joint movement stage). In the Brunnstrom staging, the hand, upper extremity and lower extremity are evaluated separately.

    Before treatment (T0) At the end of the treatment (10. week) (T1)

  • Modified Ashworth Scale

    Spasticity was planned to be evaluated with the Modified Ashworth Scale (MAS). In MAS, patients are evaluated over 5 points. 0 indicates no increase in muscle tone, and 4 indicates that the extremity is rigid in the flexion and extension directions.

    Before treatment (T0) At the end of the treatment (10. week) (T1)

  • Fugl Meyer Upper Extremity Assessment Questionnaire

    The Fugl-Meyer Upper Extremity Motor Assessment Scale (FMUE Scale) was developed to quantitatively assess sensorimotor recovery after stroke. It was prepared based on Brunnstrom\'s stages of motor recovery. The FMUE Scale consists of 33 items, each scored from 0 to 2, where 0 = cannot perform, 1 = partially performs, and 2 = fully performs. The total score is 66.

    Before treatment (T0) At the end of the treatment (10. week) (T1)

  • ABILHAND Stroke Hand Function Questionnaire

    ABILHAND Hand Questionnaire was developed in 1998 to measure the hand skill perceived by the patient. It contains 23 questions about how much difficulty the patient has in performing the activities. One of the options impossible (0 points), difficult (1 point), easy (2 points) is marked. The total score is 46.

    Before treatment (T0) At the end of the treatment (10. week) (T1)

Secondary Outcomes (3)

  • Mini Mental Test

    Before treatment (T0) At the end of the treatment (10. week) (T1)

  • Stroke Impact Survey

    Before treatment (T0) At the end of the treatment (10. week) (T1)

  • Stroke Specific Quality of Life Scale (SSQOL)

    Before treatment (T0) At the end of the treatment (10. week) (T1)

Study Arms (2)

Conventional Therapy

ACTIVE COMPARATOR

It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.

Procedure: conventional rehabilitation

Robot Assisted Therapy

EXPERIMENTAL

In addition to conventional therapy, the robotic therapy group was planned to receive robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 45 minutes, accompanied by a physiotherapist trained in robotic rehabilitation and with at least 5 years of experience. A total of 20 treatment sessions will be applied 2 days a week.

Procedure: robotic rehabilitationProcedure: conventional rehabilitation

Interventions

In addition to conventional therapy, the robotic therapy group was planned to receive robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 45 minutes, accompanied by a physiotherapist trained in robotic rehabilitation and with at least 5 years of experience. A total of 20 treatment sessions will be applied 2 days a week.

Robot Assisted Therapy

It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.

Conventional TherapyRobot Assisted Therapy

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • who were 3 months post-CVA
  • whose health status was suitable for rehabilitation
  • who could understand commands with a mini mental test score of 15 and above.

You may not qualify if:

  • Patients with persistent upper extremity pain on the hemiplegic side (VAS\>40)
  • severe spasticity in the hand (MAS≥3)
  • contracture in the hand
  • fracture or surgery on the hemiplegic side within the last 6 months
  • botulinum toxin injection into the upper extremity within the last 6 months
  • skin ulcers
  • brainstem or cerebellar lesions
  • neglect or apraxia
  • severe visual defects
  • severe depression

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

StrokeHemiplegia

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

September 3, 2024

First Posted

November 18, 2024

Study Start

December 1, 2024

Primary Completion

July 1, 2025

Study Completion

August 1, 2025

Last Updated

November 18, 2024

Record last verified: 2024-11